365telugu.com online news,October 14th,2025: Integris Medtech Limited, the second-largest India-headquartered diversified medical technology platform by operating revenue in FY25, has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for an initial public offering (IPO).
The IPO includes a fresh issue of equity shares with a face value of ₹1 each, aggregating up to ₹925 crore, and an offer for sale (OFS) of up to 21,674,531 equity shares of ₹1 each.
The OFS comprises up to 15,174,251 shares from Evercure Holdings Pte. Ltd., up to 3,250,140 shares from Gurmit Singh Chugh, and up to 3,250,140 shares from Punita Sharma.
In consultation with the Book Running Lead Managers (BRLMs), the company may pursue a pre-IPO placement of up to ₹185 crore before filing the Red Herring Prospectus (RHP) with the Registrar of Companies (ROC).
Net proceeds from the IPO will primarily be used to repay or prepay certain loans, including interest and prepayment charges, totaling ₹696.39 crore, availed by its wholly owned subsidiaries and step-down subsidiaries. The remaining funds will support general corporate purposes.
Co-founded by Gurmit Singh Chugh and Punita Sharma, Integris Medtech started with cardiology product sales and has evolved into advanced manufacturing, introducing innovations like the Yukon drug-eluting stent.
In a recent leadership move, the company appointed Probir Das as CEO, bringing over 26 years of global medtech experience from roles at Terumo and Becton Dickinson.
The company’s growth was accelerated by growth capital from Everstone Capital in 2019, enabling strategic acquisitions in Europe and the laboratory sector. These moves secured proprietary technologies for complex coronary interventions and expanded into scientific and clinical laboratories. Today, Integris is the world’s only company with two drug-eluting stent platforms: VIVO ISAR and Yukon Choice.
Its technology-led expansion is evident in acquisitions like Translumina GMBH and Blue Medical Devices in 2024 for innovation, Lamed GmbH for geographic and category diversification, and Research Instruments, Biofrontier, Analisa Resources, and Sciences Resources for leadership consolidation and market access.
In 2025, it acquired 100% of Everlife Holdings Pte Ltd. With 17 acquisitions spanning cardiovascular and laboratory solutions, Integris’s “build, partner, and acquire” strategy drives growth, addresses technology gaps, and enhances innovation and service delivery.
As a diversified India-based global medical products and laboratory solutions provider, Integris operates in two core medtech segments: cardiovascular devices (including drug-eluting stents, drug-coated balloons, complex coronary intervention products, and vascular access solutions) and laboratory solutions for clinical, research, and industrial labs.
It holds the position as India’s second-largest coronary stent manufacturer with an estimated 22.0% market share in drug-eluting stents and is Southeast Asia’s largest scientific laboratory solutions company.
The firm operates in four key markets—India, Europe, Asia (excluding India), and Rest of World (Middle East, Africa, and Latin America)—with five manufacturing facilities in India, Germany, and the Netherlands, supplying to over 65 international markets.
Integris is one of only two Indian companies producing all three classes of medical devices, manufacturing over 2,500 SKUs in-house at facilities in Dehradun (India), Hechingen (Germany), and Helmond (Netherlands).
As of June 30, 2025, the company partners with over 2,000 hospitals and cath labs and serves 9,500 laboratories globally, offering 22,000 SKUs across more than 200 brands. Its lab solutions segment represents over 200 global manufacturers, including Euroimmun, Biorad, bioMérieux, and MGI, catering to clinical and scientific labs in India and Southeast Asia.
Over 60% of revenues are derived from international markets, fueled by its global portfolio in cardiovascular, scientific lab solutions, and clinical diagnostics verticals.
Financially, Integris Medtech reported a 23.85% increase in total income to ₹1,959.58 crore in FY25 from ₹1,582.25 crore in FY24. Restated profit turned positive, swinging from a ₹4.8 crore loss in FY24 to ₹70.6 crore in FY25, while adjusted PAT rose to ₹103 crore from ₹21.4 crore.
The book-running lead managers are ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited, and IIFL Capital Services Limited (formerly IIFL Securities Limited).